KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Retained Earnings (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Retained Earnings data on record, last reported at -$15.9 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 112.44% year-over-year to -$15.9 million; the TTM value through Dec 2025 reached -$15.9 million, down 112.44%, while the annual FY2025 figure was -$15.9 million, 112.44% down from the prior year.
  • Retained Earnings reached -$15.9 million in Q4 2025 per VRTX's latest filing, down from $12.4 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $12.4 billion in Q3 2025 and bottomed at -$101.1 million in Q2 2025.
  • Average Retained Earnings over 5 years is $2.5 billion, with a median of $82.8 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 63816.81% in 2023, then plummeted 112.44% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $15.9 million in 2021, then soared by 40923.9% to $6.5 billion in 2022, then plummeted by 100.22% to -$14.3 million in 2023, then skyrocketed by 993.71% to $127.8 million in 2024, then tumbled by 112.44% to -$15.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$15.9 million in Q4 2025, $12.4 billion in Q3 2025, and -$101.1 million in Q2 2025.